Serum Institute of India chief executive officer Adar Poonawalla. File. | Photo Credit: Kamal Narang Serum Institute of India’s Chief Executive Officer Adar Poonawalla has said their Covovax vaccine will get approval as a booster against COVID-19 in the next 10 to 15 days. The vaccine works very well against the Omicron variant of coronavirus, … Read more
The Serum Institute has sought the Centre’s approval to export 32.4 lakh doses of the COVID-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer, official sources said on Thursday. According to a communication sent to the government … Read more
The Drugs Controller General of India (DCGI) on Tuesday approved India’s first indigenously developed mRNA vaccine against COVID-19 manufactured by Gennova Biopharmaceuticals for restricted emergency use for those aged 18 years and above, official sources said on Tuesday. While other mRNA vaccines require to be stored at sub-zero temperatures, Gennova’s mRNA vaccine can be stored … Read more
The subject expert committee on COVID-19 of India’s drug regulator will on Friday review the applications of Serum Institute of India seeking emergency use authorisation to use Covovax among those aged two to seven years and seven to 11 years, official sources said. The two applications were submitted by Prakash Kumar Singh, Director, Government and … Read more
The Serum Institute of India (SII) has sought permission from the country’s drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday. The Drugs Controller General of India (DCGI) had granted permission … Read more
Serum Institute of India’s coronavirus vaccine Covovax is now available for children across the country, company CEO Adar Poonawalla said on Tuesday.In a post on Twitter, he said Covovax, which has been developed by Novavax, “is now available for children in India”. He further said, “This is the only vaccine manufactured in India that is … Read more
The Standing Technical Sub-Committee of the NTAGI has recommended inclusion of the Serum Institute’s Covovax in the national COVID-19 vaccination programme for children aged 12 to 17 years, sources said on Friday. India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 … Read more
The COVID-19 Working Group of the NTAGI has recommended inclusion of the Serum Institute’s Covovax in the national vaccination programme for those aged 12 years and above, official sources said on Sunday. India’s drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, … Read more
Covid working group of NTAGI will review this week data of Serum Institute of India’s (SII) anti-coronavirus jab Covovax to decide whether it can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above, official sources said on Wednesday. India’s drug regulator had approved Covovax for restricted use in … Read more
The Novavax vaccine is manufactured and marketed in India by SII under the brand name, Covovax. The Drugs Controller General of India (DCGI) has granted emergency use authorisation (EUA) for the Novavax and Serum Institute of India (SII) Covid-19 vaccine, Covovax, in the 12-18 age group. Covovax is the fourth vaccine to receive EUA from … Read more